The content is available as a PDF (156.3 KB).
. 2021 Jul 21:gfab227. doi: 10.1093/ndt/gfab227
SARS CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?
Nestor Toapanta
1, Oriol Bestard
1, María José Soler
1,✉
Nestor Toapanta
1Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain
Find articles by Nestor Toapanta
Oriol Bestard
1Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain
Find articles by Oriol Bestard
María José Soler
1Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain
Find articles by María José Soler
1Nephrology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Research, Barcelona, Spain
✉
Corresponding Author: Dr Maria Jose Soler, E-mail: mjsoler01@gmail.com
Received 2021 May 12.
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC8344521 PMID: 34289072